DermaSensor is a pioneering medical technology company that developed the first FDA-cleared, AI-powered device for point-of-care skin cancer detection. Designed for primary care physicians, the handheld, non-invasive device uses Elastic Scattering Spectroscopy (ESS) and proprietary artificial intelligence algorithms to evaluate cellular and sub-cellular structures of suspicious skin lesions. Delivering an objective risk assessment in seconds, DermaSensor boasts a 96% sensitivity rate in detecting the three most common skin cancers: melanoma, basal cell carcinoma, and squamous cell carcinoma. This innovative tool bridges the gap in early skin cancer detection, ensuring more timely and accurate dermatology referrals.